{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:02:20Z","timestamp":1776862940127,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,4,12]],"date-time":"2013-04-12T00:00:00Z","timestamp":1365724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,4,12]],"date-time":"2013-04-12T00:00:00Z","timestamp":1365724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s10637-013-9958-3","type":"journal-article","created":{"date-parts":[[2013,4,11]],"date-time":"2013-04-11T04:28:33Z","timestamp":1365654513000},"page":"123-134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non\u2013small cell lung cancer"],"prefix":"10.1007","volume":"32","author":[{"given":"Wilfried E. E.","family":"Eberhardt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan H.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentine","family":"Jehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta R.","family":"Urva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey J.","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Gogov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Papadimitrakopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,12]]},"reference":[{"key":"9958_CR1","unstructured":"National Comprehensive Cancer Network (2011) Nccn clinical practice guidelines in oncology: non-small cell lung cancer, Version 2.2012"},{"key":"9958_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1634\/theoncologist.11-6-655","volume":"11","author":"S Ramalingam","year":"2006","unstructured":"Ramalingam S, Ab S (2006) Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist 11:655\u2013665","journal-title":"Oncologist"},{"key":"9958_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.lungcan.2012.03.019","volume":"77","author":"M Behera","year":"2012","unstructured":"Behera M, Tk O, Chen Z, Sa K, Fr K, Cp B, Ss R (2012) Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis. Lung Cancer 77:331\u2013338","journal-title":"Lung Cancer"},{"key":"9958_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1505","volume":"4","author":"B Ma","year":"2004","unstructured":"Ma B, Pj H (2004) The tor pathway: a target for cancer therapy. Nat Rev Cancer 4:335\u2013348","journal-title":"Nat Rev Cancer"},{"key":"9958_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cell.2004.12.040","volume":"120","author":"I Beuvink","year":"2005","unstructured":"Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O\u2019reilly T, Natt F, Hall J, Ha L, Thomas G (2005) The Mtor inhibitor Rad001 sensitizes tumor cells to Dna-damaged induced apoptosis through inhibition Of P21 translation. Cell 120:747\u2013759","journal-title":"Cell"},{"key":"9958_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","volume":"64","author":"A Boulay","year":"2004","unstructured":"Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O\u2019reilly T, Stolz B, Marti A, Thomas G, Ha L (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative Rad001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64:252\u2013261","journal-title":"Cancer Res"},{"key":"9958_CR7","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1158\/0008-5472.CAN-06-4490","volume":"67","author":"S Mabuchi","year":"2007","unstructured":"Mabuchi S, Da A, Dc C, Klein-Szanto A, Litwin S, Mk H, Hensley H, Tc H, Jr T (2007) Rad001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67:2408\u20132413","journal-title":"Cancer Res"},{"key":"9958_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.bcp.2009.04.033","volume":"78","author":"S La Monica","year":"2009","unstructured":"La Monica S, Galetti M, Rr A, Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M, Tagliaferri S, Mutti A, Fumarola C, Bonelli M, Generali D, Pg P (2009) Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 78:460\u2013468","journal-title":"Biochem Pharmacol"},{"key":"9958_CR9","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-09-0388","volume":"8","author":"I Nakachi","year":"2010","unstructured":"Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A (2010) The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through C-Met inhibition. Mol Cancer Res 8:1142\u20131151","journal-title":"Mol Cancer Res"},{"key":"9958_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020899","volume":"6","author":"X Cx","year":"2011","unstructured":"Cx X, Li Y, Yue P, Tk O, Ss R, Fr K, Sy S (2011) The combination of Rad001 and Nvp-Bez235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS One 6, E20899","journal-title":"PLoS One"},{"key":"9958_CR11","unstructured":"Afinitor (Everolimus) Tablets For Oral Administration [Prescribing Information] (2012) East Hanover, Nj, Usa: Novartis Pharmaceuticals Corporation"},{"key":"9958_CR12","unstructured":"Afinitor Summary Of Product Characteristics (2012) West Sussex, United Kingdom: Novartis Europharm Limited"},{"key":"9958_CR13","unstructured":"Votubia Summary Of Product Characteristics (2012) West Sussex, United Kingdom: Novartis Europharm Limited"},{"key":"9958_CR14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Ha B, Hs R, Sahmoud T, Noguchi S, Gnant M, Ki P, Lebrun F, Jt B, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Gn H (2012) Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med 366:520\u2013529","journal-title":"N Engl J Med"},{"key":"9958_CR15","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1002\/cncr.25264","volume":"116","author":"R Ss","year":"2010","unstructured":"Ss R, Rd H, Saba N, Tk O, Kauh J, Dm S, Sy S, Strychor S, Tighiouart M, Egorin Mj FH, Fr K (2010) Phase 1 and pharmacokinetic study of Everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent\/refractory nonsmall cell lung cancer. Cancer 116:3903\u20133909","journal-title":"Cancer"},{"key":"9958_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/CAD.0b013e3283400a20","volume":"22","author":"T O\u2019reilly","year":"2011","unstructured":"O\u2019reilly T, Pm M, Wartmann M, Lassota P, Brandt R, Ha L (2011) Evaluation of the Mtor inhibitor, Everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 22:58\u201378","journal-title":"Anticancer Drugs"},{"key":"9958_CR17","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Mc P, Brahmer J, Schiller J, Dowlati A, Lilenbaum R, Johnson D (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"key":"9958_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","volume":"2","author":"P Goldstraw","year":"2007","unstructured":"Goldstraw P, Crowley J, Chansky K, Dj G, Pa G, Rami-Porta R, Pe P, Rusch V, Sobin L (2007) The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706\u2013714","journal-title":"J Thorac Oncol"},{"key":"9958_CR19","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","volume":"24","author":"K Mg","year":"2006","unstructured":"Mg K, Pj H, Mr S, Feyer P, Clark-Snow R, Jm K, Gr M, Lw C, Mj C, Rj G, Sm G (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932\u20132947","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"9958_CR20","doi-asserted-by":"publisher","first-page":"I77","DOI":"10.1093\/annonc\/mdi805","volume":"16","author":"J Herrstedt","year":"2005","unstructured":"Herrstedt J, Ms A, Roila F, Vv K (2005) ESMO minimum clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (Nv). Ann Oncol 16(Suppl 1):I77\u2013I79","journal-title":"Ann Oncol"},{"key":"9958_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Sg A, Ea E, Wanders J, Rs K, Rubinstein L, Verweij J, Van Glabbeke M, At VO, Mc C, Sg G (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"9958_CR22","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","volume":"26","author":"J Tabernero","year":"2008","unstructured":"Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Fj R, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Ha L, Lebwohl D, Baselga J (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603\u20131610","journal-title":"J Clin Oncol"},{"key":"9958_CR23","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","volume":"26","author":"A O\u2019donnell","year":"2008","unstructured":"O\u2019donnell A, Faivre S, Ha B, Iii RD, Papadimitrakopoulou V, Shand N, Ha L, Hazell K, Zoellner U, Jm K, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588\u20131595","journal-title":"J Clin Oncol"},{"key":"9958_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1756-8722-4-3","volume":"4","author":"B Xu","year":"2011","unstructured":"Xu B, Wu Y, Shen L, Ye D, Jappe A, Cherfi A, Wang H, Yuan R (2011) Two dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. J Hematol Oncol 4:3","journal-title":"J Hematol Oncol"},{"key":"9958_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jjco\/hyp120","volume":"40","author":"I Okamoto","year":"2010","unstructured":"Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K, Kobayashi K, Nakagawa K (2010) Phase I clinical and pharmacokinetic study of Rad001 (Everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 40:17\u201323","journal-title":"Jpn J Clin Oncol"},{"key":"9958_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/cncr.22816","volume":"110","author":"M Dt","year":"2007","unstructured":"Dt M, Gj R, Cg A, Je G, Rt H, Mg K, Lm K, Pao W, Pizzo B, Na R, Va M (2007) Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 110:599\u2013605","journal-title":"Cancer"},{"key":"9958_CR27","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1097\/JTO.0b013e3182307ede","volume":"6","author":"J Vansteenkiste","year":"2011","unstructured":"Vansteenkiste J, Solomon B, Boyer M, Wolf J, Miller N, Sl D, Pylvaenaeinen I, Petrovic K, Dimitrijevic S, Anrys B, Laack E (2011) Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model. J Thorac Oncol 6:2120\u20132129","journal-title":"J Thorac Oncol"},{"key":"9958_CR28","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1002\/cncr.25931","volume":"117","author":"H Al","year":"2011","unstructured":"Al H, Ej S, Vk W, Sun J, Cj R, Am L, Fong L, Dr B, Je R (2011) A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 117:4194\u20134200","journal-title":"Cancer"},{"key":"9958_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00280-010-1507-6","volume":"67","author":"B Ke","year":"2011","unstructured":"Ke B, Wp P, Younis I, He U, Ma M, Gc B, Sy Z, Jp G, Jj L, Truax R, Kl M, La H, Mm O\u2019n, Broadwater G, Hi H, Jc B (2011) A Phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (Bee). Cancer Chemother Pharmacol 67:465\u2013474","journal-title":"Cancer Chemother Pharmacol"},{"key":"9958_CR30","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"Y Jc","year":"2011","unstructured":"Jc Y, Shah M, Ito T, Cl B, Em W, Van Cutsem E, Tj H, Okusaka T, Capdevila J, Eg DV, Tomassetti P, Me P, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514\u2013523","journal-title":"N Engl J Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9958-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-9958-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9958-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9958-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:43:21Z","timestamp":1678509801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-9958-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["9958"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-9958-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,12]]},"assertion":[{"value":"13 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}